Artiva Biotherapeutics周二表示，在两名接受该疗法试验的患者死亡后，公司将停止针对某些自身免疫性疾病的实验性细胞疗法的开发，其股价在盘前交易中下跌30%。
Artiva Biotherapeutics said on Tuesday it would halt the development of its experimental cell therapy for certain autoimmune conditions after two deaths among patients who were being tested on the treatment, sending its shares down 30% in premarket trading.